Articles tagged with Immunotherapy
Chemotherapies like CarboTaxol enhance cancer vaccine responses by expanding a pool of T cells that express the factor TCF1, rejuvenating their life and functionality. This effect is further enhanced when combined with immunotherapy, showing potential for improved clinical trial outcomes.
Researchers are exploring biomarker-guided patient selection and combination therapies to overcome glioblastoma's biological barriers. Agents targeting tumor metabolism, immunotherapies, and oncolytic viruses are being investigated.
In vivo CAR-T therapy reduces manufacturing time and cost, enabling more accessible cancer immunotherapy. The strategy also enables superior self-renewal capacity and anti-tumor persistence.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.
A retrospective analysis of 20,000 patient records found that patients receiving immunotherapy and multiple immunosuppressive therapies were at higher risk of severe infections. Treatment with multiple immunosuppressive therapies was associated with increased rates and severity of infection.
Scientists found that the gene ZMYND8 drives T-cell exhaustion, revealing a new strategy to improve anti-tumor and anti-viral immune responses. Removing ZMYND8 improves anti-tumor and anti-viral responses on its own, and shows potential synergy in combination with immunotherapy.
Researchers at Bar-Ilan University and Weizmann Institute successfully engineered immune cells to recognize and attack cancer and viral targets. The enhanced T cells demonstrated stronger immune responses and greater cancer-killing ability, improving survival in mice.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Research by Professor Dong Zhang's team identifies IFITM1 as a key regulator of mitophagy, essential for maintaining the anti-tumor activity of double-negative T cells. This mechanism provides a promising strategy for optimizing TCRαβ+CD4-CD8- T cell therapies.
Hepatocellular carcinoma (HCC) cells upregulate lipid uptake, de novo lipogenesis, and fatty acid oxidation, supporting tumour growth and metastasis. Targeting lipid metabolism, including CE synthesis and lipid biosynthetic enzymes, shows synergistic effects with antitumour drugs.
Researchers identified a link between B cell activity and immunotherapy-related colitis, a common side effect of cancer treatments. Higher B cell levels before treatment were associated with increased colitis risk, and depleting B cells reduced colitis severity.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
Researchers have developed a computational framework to design and fabricate crisscross DNA megastructures, expanding accessibility to DNA nanotechnology. This breakthrough enables the construction of complex structures with precise control, opening up new avenues for applications in fields like optics, immunology, and tissue engineering.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
A new review in Science Bulletin outlines how multimodal AI can integrate molecular, cellular, and clinical data to refine treatment choices and predict side effects. The approach aims to address challenges in cancer treatment, including primary resistance and immune-related adverse events.
The study confirms the durability of benefit for pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer. This treatment regimen has been shown to provide a significant advantage over traditional chemotherapy in patients with this type of cancer.
Acute myeloid leukemia (AML) remains difficult to treat with immunotherapy due to its ability to evade the immune system. The study aims to understand how immune cells recognize leukemia cells without relying on HLA, with the goal of developing HLA-independent immunotherapies.
Salk Institute researchers have discovered a novel pathway that links chronic interferon II exposure to mitochondrial dysfunction, leading to immunosuppression and enhanced tumor growth. By blocking prostaglandin E2, they found a viable target to restore immune system function and combat immunotherapy resistance.
Researchers found that pancreatic cancer cells create localized immune-protective niches that shield tumors from immune attack. Disrupting these protective mechanisms slowed tumor growth and improved responses to immunotherapy in preclinical models.
Researchers found that methylglyoxal stress stimulates the expansion of immunosuppressive cells, which can help cancer evade immune surveillance. The study also identified a potential biomarker for predicting response to immunotherapy.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
Researchers discovered that cancer cells use an antioxidant protein to suppress T cells, allowing them to evade the immune system. This finding identifies a promising new target for cancer immunotherapy, potentially helping to overcome treatment resistance and improve patient outcomes.
Children's Hospital Colorado has launched a Sublingual Immunotherapy Program to treat children with 10 common food allergies, including milk, egg, peanut, and sesame. The program involves daily liquid drops under the tongue and may gradually build tolerance and provide greater protection against accidental exposure.
Tumor-infiltrating lymphocyte therapy has shown potential in several types of solid tumors, including metastatic melanoma, breast cancer, and ovarian cancer. Despite challenges, the approach has favorable clinical outcomes, and researchers are exploring combination strategies and advanced technologies to improve treatment durability.
Researchers developed tools to compare tumor microenvironments and predict treatment response by analyzing spatial transcriptomic data. The new tools provide a detailed map of tumor cell organization, enabling clinicians to quickly analyze and compare tumor 'floor plans' and determine the best course of treatment.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.
Researchers discovered how tumors interact with the body to grow and spread, revealing a new target for cancer therapy. Metadherin, a protein encoded by the MTDH gene, mediates this metabolic-immune crosstalk, supporting tumor growth and metastasis.
UCSF scientists have invented a way to treat cancer with teacher cells and tumor pieces, combining immune cells grown in the lab with patient tumor samples. The method uses dendritic cells to train T cells to recognize and destroy cancer cells, offering a promising approach to immunotherapy.
A new study from Arizona State University finds that past immune encounters can predict future vaccine response, opening a path toward more personalized vaccination strategies. Researchers analyzed blood samples from over 4,000 people, identifying antibody signatures that distinguish strong responders from weak ones.
Researchers discovered that exhausted T cells can lose the exhaustion marker LAG3 to escape tumors and confer long-lasting immunity to cancer in mice. These cells play a critical role in generating a strong, durable memory response, which is essential for effective cancer immunotherapy.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
A new study identifies MSLN, TROP-2, and LIV-1 as potential therapeutic targets for cervical cancer, with distinct profiles across tumor subtypes. LIV-1 may represent a precision medicine target for a biologically defined subgroup of cervical cancer patients.
A new strategy remodels the cell membrane to convert ordinary macrophages into pathogen-targeting immune cells. Engineered macrophages successfully overcame limitations of conventional antimicrobial therapies, demonstrating improved bacterial recognition and elimination.
The PolyU developed AI Virtual Patient Simulation System combines multimodal data from genomic, medical imaging and clinical records to create a digital twin model tracking real-time changes in a patient's condition. It predicts the effectiveness of different cancer treatment options and supports personalized medical solutions.
A study maps how antibodies target a key region of the SARS-CoV-2 spike protein, neutralizing the virus, and how emerging variants escape. Researchers identified three immune escape strategies: disruption, glycan shielding, and conformational remodeling.
Researchers from the University of Rochester's TraCe-bMPS have developed tissue chips that can predict dangerous immune reactions to cancer therapies. The technology, which uses human cells and sensors, has been accepted into the FDA's Innovative Science and Technology Approaches for New Drugs pilot program.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A single-cell atlas reveals that a balance between two macrophage states, with lipid-fueled immunesupressors, tracks clinical outcomes in gastric cancer patients. Tumors with a more permissive immune state respond better to immunotherapy and have longer progression-free survival.
Researchers identified two immune cell populations present in both initial and recurrent arthritis flares, suggesting an immune-memory disease. These cells may serve as biomarkers for high-risk patients or to guide targeted therapies to reduce side effects.
Researchers develop new CAR-T engineering strategies to address the barriers of solid tumors, including tumor access, targeting specificity, cellular resilience, and patient physiological context. The approaches aim to build cellular fitness and overcome immunosuppressive signals, with promising results in clinical trials.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center are developing drug-based strategies to enhance cancer immunotherapy for melanoma and potentially other cancers. They identified two promising compounds that could strengthen T cell interaction with cancer cells or make tumor cells more susceptible to destruction by T cells.
Researchers found that tumor cells use DDB1 to ubiquitinate PD-L1, allowing it to enter the nucleus and drive immune suppression. A new compound, thalidomide, disrupts this process, restoring sensitivity to immunotherapy in preclinical breast cancer models.
A blood test that detects circulating tumor DNA can predict whether patients with advanced non-small cell lung cancer are benefiting from immunotherapy. The test was found to be accurate in predicting therapy response and can provide clinically meaningful information weeks before conventional imaging.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
A phase 2 clinical trial found that combining two immunotherapies with standard chemotherapy prior to surgery improved pathologic complete response rates in high-risk, early-stage HER2-negative breast cancer patients. The regimen demonstrated strong activity among patients with ImPrint-positive tumors, including high pCR rates.
Researchers developed a quantum machine learning framework to predict which tumor mutations will trigger an immune response. The Q-CHIPP model outperformed classical computing methods and achieved a significant technical milestone by scaling to full-length peptide modeling on quantum hardware.
Researchers have identified a new strategy to prevent T cell exhaustion and boost immunotherapy by blocking MEK signaling. This approach has shown promise in lab models, enabling T cells to persist under harsh tumor conditions. However, the effectiveness of this treatment may vary among patients due to the complexity of T cell exhaustion.
A new study reveals that p53 mutations in cancer cells can limit the effectiveness of immunotherapy by manipulating cellular metabolism, specifically through autophagy. Removing these mutant forms of p53 restores mTORC1 activity and reduces autophagy, making tumors more vulnerable to immune attack.
A subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others. Researchers from the Keck School of Medicine of USC identified a biological feedback loop that helps activate the immune response against these types of cancer.
A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...
Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.
Researchers created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study identified five distinct subtypes, or 'ecotypes,' that capture meaningful insights into signaling pathways and genetic programs not fully explained by disease stage alone.
Hepatocellular carcinoma (HCC) gene signatures can predict prognosis and respond to immune checkpoint inhibitors. However, validating these signatures across different platforms and overcoming ethical concerns hinder their widespread adoption. Integrating multi-omics approaches with liquid biopsy holds promise for personalized therapy,...
Researchers from the University of Nebraska-Lincoln have identified a specific gut bacterium, Bacteroides uniformis, and its metabolites that can positively impact the body's immune response to cancer. The study found that these metabolites can suppress tumor growth and boost anti-tumor immunity in mice.
A new method called ATTACH identifies strong interactions between T cells and cancer-specific proteins to isolate effective tumor-reactive T cells. This approach overcomes key challenges in immunotherapy development, offering a rapid and accessible way for isolating rare immune cells.
The new journal features cutting-edge research across basic, clinical, and translational immunology. It is designed to connect researchers across the full breadth of immunology, deepening understanding of the immune system in health and disease.
A team of researchers has developed chimeric allergen receptors that can suppress the immune system's response to common allergens, reducing or preventing asthma symptoms in mice. The technique could eventually be used to treat a wide variety of allergies in humans.
The Ludwig Institute for Cancer Research has appointed three Clinical Scholars, Bernhard Gentner, Caroline Arber, and Christian Hinrichs, to advance cancer research and clinical interventions. The new scholars will focus on translating scientific discoveries into clinical trials and partnerships with leading clinical facilities.